As increased TRIM21/Ro52 expression was associated with better outcomes in ovarian cancer in recent research, whether the antibody impairs TRIM21/Ro52 protein function or the presence of anti-TRIM21/Ro52 antibodies reflects the overexpression phenomenon of TRIM21/Ro52 in cancer requires further investigation [42]. Here, TRIM21 is linked to ovarian carcinoma.